Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis

Arthritis Care and Research

Volumn 64, Issue 12, 2012, Pages 1804-1810

  Maska, Leann B ^a   Sayles, Harlan R ^a   O'Dell, James R ^a   Curtis, Jeffrey R ^b   Bridges, S Louis ^b   Moreland, Larry W ^c   Cofield, Stacey S ^b   Mikuls, Ted R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SMOKING; TOBACCO; TREATMENT RESPONSE;

EID: 84870566756     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21758     Document Type: Article

References (32)

1. Criswell LA, Merlino LA, Cerhan JR, Mikuls TR, Mudano AS, Burma M, et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med 2002; 112: 465-71.
2. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al, and the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
3. Karlson EW, Chang SC, Cui J, Chibnik LB, Fraser PA, De Vivo I, et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis 2010; 69: 54-60.
4. Bridges SL Jr, Hughes LB, Mikuls TR, Howard G, Tiwari HK, Alarcon GS, et al. Early rheumatoid arthritis in African-Americans: the CLEAR Registry. Clin Exp Rheumatol 2003; 21: S138-45.
5. Costenbader KH, Feskanich D, Mandl LA, Karlson EW,. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006; 119: 503.e1-9.
6. Lee HS, Irigoyen P, Kern M, Lee A, Batliwalla F, Khalili H, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007; 56: 1745-53.
7. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8: R133.
8. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L, for the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50: 3085-92.
9. Nyhall-Wahlin BM, Petersson IF, Nilsson JA, Jacobsson LT, Turesson C, for the BARFOT Study Group. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 416-20.
10. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL,. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722-7.
11. Kim SK, Park SH, Shin IH, Choe JY,. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. J Rheumatol 2008; 35: 995-1001.
12. Mikuls TR, Hughes LB, Westfall AO, Holers VM, Parrish L, van der Heijde D, et al. Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1529-34.
13. Nyhall-Wahlin BM, Jacobsson LT, Petersson IF, Turesson C, for the BARFOT Study Group. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 2006; 65: 601-6.
14. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008; 168: 159-66.
15. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183: 372-8.
16. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL,. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29: 62-7.
17. Westhoff G, Rau R, Zink A,. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) 2008; 47: 849-54.
18. Hyrich KL, Watson KD, Silman AJ, Symmons DP, for the British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
19. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St.Clair EW, et al, for the TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012; 64: 2824-35.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
21. Koru-Sengul T, Clark JD, Fleming LE, Lee DJ,. Toward improved statistical methods for analyzing cotinine-biomarker health association data. Tob Induc Dis 2011; 9: 11.
22. Florescu A, Ferrence R, Einarson T, Selby P, Soldin O, Koren G,. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther Drug Monit 2009; 31: 14-30.
23. Mikuls TR, Kazi S, Cipher D, Hooker R, Kerr GS, Richards JS, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol 2007; 34: 1480-4.
24. Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 2011; 50: 101-9.
25. Jarvis MJ, Russell MA, Benowitz NL, Feyerabend C,. Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. Am J Public Health 1988; 78: 696-8.
26. Van Gestel AM, Haagsma CJ, van Riel PL,. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
27. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE,. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300.
28. Franklin J, Lunt M, Bunn D, Symmons D, Silman A,. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007; 66: 308-12.
29. Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM,. Anti-TNF-α agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 2010; 16: 15-8.
30. Mattey DL, Brownfield A, Dawes PT,. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1180-7.
31. Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT Trial. Ann Rheum Dis 2011; 70: 469-75.
32. Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011; 63: 26-36.